Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.45 |
| ▸ | PPP5C | P53041 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | GSR | P00390 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8969980 | 1.00 | GBA1 (0.45) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL18605847 | 1.00 | GBA1 (0.45) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL7195617 | 0.96 | GBA1 (0.45) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL13326285 | 0.96 | GBA1 (0.45) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL5831411 | 0.94 | GBA1 (0.44) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL8970045 | 0.94 | GBA1 (0.51) | GBA1GBA2 | |
| SCHEMBL8969080 | 0.94 | GBA1 (0.44) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL19526296 | 0.94 | GBA1 (0.44) | GBA1PPP5CCA1CA2CA4 | |
| SCHEMBL8969385 | 0.92 | GBA1 (0.54) | GBA1GBA2 | |
| SCHEMBL8970314 | 0.92 | GBA1 (0.54) | GBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK2, NTRK3, NTRK1 | GBA1 1485/4885PPP5C 114/4885CA1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.